+6504738654

## RECEIVED CENTRAL FAX CENTER

DEC 0 6 2006

Appl. No. 10/602,441 (Docket 086/002) Amdt. dated December 6, 2006 Reply to Office Action of June 6, 2006

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

What is claimed as the invention is:

- 1. (Currently amended) A method for eliciting an immune response in a mammalian-subject <a href="https://doi.org/10.10/10.10/">https://doi.org/10.10/</a> A method for eliciting an immune response in a mammalian-subject <a href="https://doi.org/10.10/">https://doi.org/10.10/</a> A method for eliciting an immune response in a mammalian elementary that is specific for its own to <a href="https://doi.org/10.10/">https://doi.org/10.10/</a> A method for eliciting an immune response in a mammalian elementary transcriptase (TERT), comprising administering to the subject <a href="https://doi.org/10.10/">https://doi.org/10.10/</a> A method for eliciting an immune response in a mammalian elementary transcriptase (TERT), comprising administering to the subject <a href="https://doi.org/10.10/">https://doi.org/10.10/</a> A method for eliciting an immune response in a mammalian elementary transcriptase (TERT), comprising administering to the subject <a href="https://doi.org/10.10/">https://doi.org/10.10/</a> A method for eliciting an immune response in a mammalian elementary transcriptase (TERT), comprising administering to the subject <a href="https://doi.org/10.10/">https://doi.org/10.10/</a> A method for eliciting an immune response in a mammalian elementary transcriptase (TERT), comprising administering to the subject <a href="https://doi.org/10.10/">https://doi.org/10.10/</a> A method for eliciting an immune response in a mammalian elementary transcriptase (TERT), comprising administering to the subject <a href="https://doi.org/10.10/">https://doi.org/10.10/</a> A method for eliciting an immune response reverse transcriptase (TERT), comprising administering to the subject <a href="https://doi.org/10.10/">https://doi.org/10.10/</a> A method for eliciting an immune response reverse transcriptase (TERT), comprising administering to the subject <a href="https://doi.org/10.10/">https://doi.org/10.10/</a> A method for eliciting an immune response reverse transcriptase (TERT), comprising a method for eliciting an immune respons
- (Currently amended) The method of claim 1, wherein the protein comprises at least 100
  consecutive amino acids of TERT of the other mammalian species a non-human mammalian
  species.
- 3. (Currently amended) The method of claim 1, comprising administering the protein or nucleic acid to the subject human on at least four different occasions.
- 4. (Currently amended) The method of claim 1, further comprising subsequently administering a second composition containing a second protein with at least 20 consecutive amino acids of TERT of the same species as the subject, or a nucleic acid encoding said second protein a protein with at least 20 consecutive amino acids of human TERT.
- 5. (Original) The method of claim 1, which elicits a cytotoxic T cell response.

- 6. (Currently amended) The method of claim 1, wherein the protein is a full-length TERT.
- 7.-8. (Canceled)
- 9. (Currently amended) The method of claim 1, wherein the composition contains either:

  a plurality of different proteins, each comprising at least 20 consecutive amine acids of

  TERT from one or more mammalian species different from the mammalian subject to which

  the composition is administered, or

  one or more nucleic acids encoding eaid plurality of proteins a plurality of different proteins,

  each comprising at least 20 consecutive amino acids of TERT from one or more non-human

  mammalian species.
- 10. (Currently amended) The method of claim 1, wherein the protein comprises at least 20 consecutive amino acids of any of SEQ. ID NOs: 4, 6, 8, and 10, and 12.
- 11. (Original) The method of claim 1, wherein the composition contains an adenovirus expression vector encoding the protein.
- 12. (Original) The method of claim 1, wherein the composition also contains a factor selected from IL-12, GM-CSF, IL-2 and MPL.
- 13. 24. (Canceled)